Giulia Gorrieri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giulia Gorrieri has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Paolo Scudieri
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy
4 shared publications - Federico Zara
Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy
2 shared publications Ilaria Musante
Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
2 shared publications- Ambra Gianotti
U.O.C. Genetica Medica, Istituto Giannina Gaslini, Genova, Italy
1 shared publication - Damian Mojsak
2nd Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, 15-540 Bialystok, Poland
1 shared publication Diego Carrella
Telethon Institute of Genetics and Medicine, Pozzuoli, Italy
1 shared publication
Latest Publications
- Open Access
- 27 August 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
Human nasal epithelial cells as an integrated platform for biomarker discovery, functional airway studies, and patient-specific stem cell generation
Studying epithelial dysfunction in respiratory diseases requires physiologically relevant human models that faithfully recapitulate airway structure and function. Primary human nasal epithelial cells (hNECs) represent an accessible and clinically validated system, widely used for mutation-specific drug theratyping. However, the broader potential of hNECs as an integrated experimental platform remains underexplored. Here, we establish a customized hNEC-based platform spanning ex vivo, in vitro, and stem cell-based applications, with direct relevance to precision medicine. Using freshly fixed nasal brushings, we developed a quantitative single-cell metric to assess Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) localization at the ionocyte plasma membrane, identifying a candidate ex vivo biomarker sensitive to disease status and pharmacological modulation in cystic fibrosis (CF). In parallel, transcriptomic profiling demonstrated that air-liquid interface-differentiated hNECs closely recapitulate the molecular features of native nasal epithelium. Functionally, differentiated hNECs reproduced key properties of airway surface liquid (ASL) physiology and its dysregulation under inflammatory and CF conditions. Finally, we show that basal hNECs provide a robust and accessible source for induced pluripotent stem cell (iPSC) generation. hNEC-derived iPSCs exhibited canonical pluripotency features, differentiated efficiently into germ layer derivatives and lung progenitors, and displayed transcriptomic profiles indistinguishable from iPSCs generated from other somatic sources, supporting their suitability for patient-specific disease modeling. Collectively, these findings position hNECs as an integrated, patient-specific platform linking ex vivo biomarker discovery, in vitro functional assays, and stem cell–based modeling, thereby expanding their utility for precision medicine.
- 27 August 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
Open AccessHuman nasal epithelial cells as an integrated platform for biomarker discovery, functional airway studies, and patient-specific stem cell generation
Studying epithelial dysfunction in respiratory diseases requires physiologically relevant human models that faithfully recapitulate airway structure and function. Primary human nasal epithelial cells (hNECs) represent an accessible and clinically validated system, widely used for mutation-specific drug theratyping. However, the broader potential of hNECs as an integrated experimental platform remains underexplored. Here, we establish a customized hNEC-based platform spanning ex vivo, in vitro, and stem cell-based applications, with direct relevance to precision medicine. Using freshly fixed nasal brushings, we developed a quantitative single-cell metric to assess Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) localization at the ionocyte plasma membrane, identifying a candidate ex vivo biomarker sensitive to disease status and pharmacological modulation in cystic fibrosis (CF). In parallel, transcriptomic profiling demonstrated that air-liquid interface-differentiated hNECs closely recapitulate the molecular features of native nasal epithelium. Functionally, differentiated hNECs reproduced key properties of airway surface liquid (ASL) physiology and its dysregulation under inflammatory and CF conditions. Finally, we show that basal hNECs provide a robust and accessible source for induced pluripotent stem cell (iPSC) generation. hNEC-derived iPSCs exhibited canonical pluripotency features, differentiated efficiently into germ layer derivatives and lung progenitors, and displayed transcriptomic profiles indistinguishable from iPSCs generated from other somatic sources, supporting their suitability for patient-specific disease modeling. Collectively, these findings position hNECs as an integrated, patient-specific platform linking ex vivo biomarker discovery, in vitro functional assays, and stem cell–based modeling, thereby expanding their utility for precision medicine.
- Open Access
- 27 September 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (10) , 1455
ATP12A Proton Pump as an Emerging Therapeutic Target in Cystic Fibrosis and Other Respiratory Diseases
ATP12A encodes the catalytic subunit of the non-gastric proton pump, which is expressed in many epithelial tissues and mediates the secretion of protons in exchange for potassium ions. In the airways, ATP12A-dependent proton secretion contributes to complex mechanisms regulating the composition and properties of the fluid and mucus lining the respiratory epithelia, which are essential to maintain the airway host defense and the respiratory health. Increased expression and activity of ATP12A in combination with the loss of other balancing activities, such as the bicarbonate secretion mediated by CFTR, leads to excessive acidification of the airway surface liquid and mucus dysfunction, processes that play relevant roles in the pathogenesis of cystic fibrosis and other chronic inflammatory respiratory disorders. In this review, we summarize the findings dealing with ATP12A expression, function, and modulation in the airways, which led to the consideration of ATP12A as a potential therapeutic target for the treatment of cystic fibrosis and other airway diseases; we also highlight the current advances and gaps regarding the development of therapeutic strategies aimed at ATP12A inhibition.
- 27 September 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (10) , 1455
Open AccessATP12A Proton Pump as an Emerging Therapeutic Target in Cystic Fibrosis and Other Respiratory Diseases
ATP12A encodes the catalytic subunit of the non-gastric proton pump, which is expressed in many epithelial tissues and mediates the secretion of protons in exchange for potassium ions. In the airways, ATP12A-dependent proton secretion contributes to complex mechanisms regulating the composition and properties of the fluid and mucus lining the respiratory epithelia, which are essential to maintain the airway host defense and the respiratory health. Increased expression and activity of ATP12A in combination with the loss of other balancing activities, such as the bicarbonate secretion mediated by CFTR, leads to excessive acidification of the airway surface liquid and mucus dysfunction, processes that play relevant roles in the pathogenesis of cystic fibrosis and other chronic inflammatory respiratory disorders. In this review, we summarize the findings dealing with ATP12A expression, function, and modulation in the airways, which led to the consideration of ATP12A as a potential therapeutic target for the treatment of cystic fibrosis and other airway diseases; we also highlight the current advances and gaps regarding the development of therapeutic strategies aimed at ATP12A inhibition.
- Open Access
- 25 January 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (2) , 202
SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease
SLC26A9 belongs to the solute carrier family 26 (SLC26), which comprises membrane proteins involved in ion transport mechanisms. On the basis of different preliminary findings, including the phenotype of SlC26A9-deficient mice and its possible role as a gene modifier of the human phenotype and treatment response, SLC26A9 has emerged as one of the most interesting alternative targets for the treatment of cystic fibrosis (CF). However, despite relevant clues, some open issues and controversies remain. The lack of specific pharmacological modulators, the elusive expression reported in the airways, and its complex relationships with CFTR and the CF phenotype prevent us from conclusively understanding the contribution of SLC26A9 in human lung physiology and its real potential as a therapeutic target in CF. In this review, we summarized the various studies dealing with SLC26A9 expression, molecular structure, and function as an anion channel or transporter; its interaction and functional relationships with CFTR; and its role as a gene modifier and tried to reconcile them in order to highlight the current understanding and the gap in knowledge regarding the contribution of SLC26A9 to human lung physiology and CF disease and treatment.
- 25 January 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (2) , 202
Open AccessSLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease
SLC26A9 belongs to the solute carrier family 26 (SLC26), which comprises membrane proteins involved in ion transport mechanisms. On the basis of different preliminary findings, including the phenotype of SlC26A9-deficient mice and its possible role as a gene modifier of the human phenotype and treatment response, SLC26A9 has emerged as one of the most interesting alternative targets for the treatment of cystic fibrosis (CF). However, despite relevant clues, some open issues and controversies remain. The lack of specific pharmacological modulators, the elusive expression reported in the airways, and its complex relationships with CFTR and the CF phenotype prevent us from conclusively understanding the contribution of SLC26A9 in human lung physiology and its real potential as a therapeutic target in CF. In this review, we summarized the various studies dealing with SLC26A9 expression, molecular structure, and function as an anion channel or transporter; its interaction and functional relationships with CFTR; and its role as a gene modifier and tried to reconcile them in order to highlight the current understanding and the gap in knowledge regarding the contribution of SLC26A9 to human lung physiology and CF disease and treatment.
- Open Access
- 27 October 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 36016
Goblet Cell Hyperplasia Requires High Bicarbonate Transport To Support Mucin Release
Goblet cell hyperplasia, a feature of asthma and other respiratory diseases, is driven by the Th-2 cytokines IL-4 and IL-13. In human bronchial epithelial cells, we find that IL-4 induces the expression of many genes coding for ion channels and transporters, including TMEM16A, SLC26A4, SLC12A2, and ATP12A. At the functional level, we find that IL-4 enhances calcium- and cAMP-activated chloride/bicarbonate secretion, resulting in high bicarbonate concentration and alkaline pH in the fluid covering the apical surface of epithelia. Importantly, mucin release, elicited by purinergic stimulation, requires the presence of bicarbonate in the basolateral solution and is defective in cells derived from cystic fibrosis patients. In conclusion, our results suggest that Th-2 cytokines induce a profound change in expression and function in multiple ion channels and transporters that results in enhanced bicarbonate transport ability. This change is required as an important mechanism to favor release and clearance of mucus.
- 27 October 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 36016
Open AccessGoblet Cell Hyperplasia Requires High Bicarbonate Transport To Support Mucin Release
Goblet cell hyperplasia, a feature of asthma and other respiratory diseases, is driven by the Th-2 cytokines IL-4 and IL-13. In human bronchial epithelial cells, we find that IL-4 induces the expression of many genes coding for ion channels and transporters, including TMEM16A, SLC26A4, SLC12A2, and ATP12A. At the functional level, we find that IL-4 enhances calcium- and cAMP-activated chloride/bicarbonate secretion, resulting in high bicarbonate concentration and alkaline pH in the fluid covering the apical surface of epithelia. Importantly, mucin release, elicited by purinergic stimulation, requires the presence of bicarbonate in the basolateral solution and is defective in cells derived from cystic fibrosis patients. In conclusion, our results suggest that Th-2 cytokines induce a profound change in expression and function in multiple ion channels and transporters that results in enhanced bicarbonate transport ability. This change is required as an important mechanism to favor release and clearance of mucus.